RxDoctor Payments Data

Daniel Hanley, MD

Family Medicine · Bokeelia, FLNPI 1407268600

Payments from drug & device makers

$442in general payments, 2019–2025

Across 23 payments — averaging $19.20 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • GSK$173
  • Lilly USA, LLC$103
  • Novo Nordisk$80
  • Amgen$30
  • Lucid Diagnostics Inc.$21
  • AstraZeneca$20
  • plus $15 from 1 others

What the payments were for

  • Food & beverage$442100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
GSK10$173
Lilly USA, LLC4$103
Novo Nordisk4$80
Amgen2$30
Lucid Diagnostics Inc.1$21
AstraZeneca1$20
Pfizer1$15

How this compares

$442 in reported general payments places this provider in the 45th percentile of 7,282 family medicine providers in Florida.

See all family medicine providers in Florida

Medicare billing

Part B allowed, 2024
$365,453
Medicare patients
512
Services billed
3,518

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide161$223,535
MounjaroTirzepatide110$166,543
Trelegy ElliptaFluticasone/Umeclidin/Vilanter65$83,860
EliquisApixaban43$50,086
XareltoRivaroxaban30$39,720
TrulicityDulaglutide22$31,385
JardianceEmpagliflozin34$27,998
MyrbetriqMirabegron21$14,579
FarxigaDapagliflozin Propanediol13$11,490
Breo ElliptaFluticasone/Vilanterol14$7,677
Ezetimibe-SimvastatinEzetimibe/Simvastatin67$3,142
Levothyroxine Sodium262$2,994
Metoprolol Succinate198$2,687
Omeprazole169$2,502
Atorvastatin Calcium306$2,501

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$80$223,535161 claims
Lilly USA, LLCMounjaro, Trulicity$103$197,928132 claims
GSKTrelegy Ellipta, Breo Ellipta$173$91,53779 claims
PfizerEliquis$15$50,08643 claims
AstraZenecaFarxiga$20$11,49013 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 45th percentile of 7,282 family medicine providers in Florida.

Other family medicine in Bokeelia

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →